Add-on therapy for pulmonary fibrosis, a forthcoming era with implications for practice: the BI 101550 and RELIEF trials.

Lurdes Planas-CerezalesLaura FabbriLaurence Pearmain

Published in: Breathe (Sheffield, England) (2023)

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021; 9: 476-486.

Keyphrases

idiopathic pulmonary fibrosis
placebo controlled
pulmonary fibrosis
phase iii
double blind
study protocol
phase ii
clinical trial
open label
interstitial lung disease
multiple sclerosis
primary care
phase ii study
randomized controlled trial
healthcare
quality improvement
squamous cell carcinoma
radiation therapy